Dianthus Therapeutics Inc. logo

Dianthus Therapeutics Inc.

DNTH | NASDAQ
Chart Builder DCF Calculator
$96.47
-$0.34 (-0.35%)
At close: Sep 21, 2026, 4:00 PM ET
$96.47
$0 (0.00%)
After-hours: Sep 21, 2026, 7:30 PM ET

Market Data

Market Cap
$5.4B
Enterprise Value
$4.51B
Beta
0.08
Average Volume
890.12K
Shares Outstanding (Diluted)
56.03M
Shares Change YoY
56.41%
Institutional Ownership
N/A
Exchange
NASDAQ
ISIN
US2528281080

Price Performance

Price Change 1M
-12.4%
Price Change 3M
10.2%
Price Change 6M
21.2%
Price Change YTD
143.1%
Price Change 1Y
155.5%
Price Change 3Y
619.9%
Price Change 5Y
-19.3%
1M CAGR (ann.)
-11.4%
1Y CAGR (ann.)
148.2%
5Y CAGR (ann.)
-0.8%
All-Time CAGR
-10.1%

Valuation

PE Ratio
-742.08
Forward PE
N/A
PEG Ratio
122.51
Forward PEG
-35.96
PS Ratio
2,834.03
Forward PS
2,661.20
PB Ratio
4.60
P/FCF Ratio
-29.23
P/Adj. FCF Ratio
-23.52
P/OCF Ratio
-34.83
EV/Sales
2,368.94
EV/EBIT
-150.81
EV/EBITDA
-152.85
EV/FCF
-24.44
Earnings Yield
-0.1%
FCF Yield
-3.4%
Adj. FCF Yield
-4.3%

Financial Health

Net Cash
$886.81M
Total Debt
$1.29M
Cash & Short-Term Investments
$886.81M
Total Assets
$1.21B
Current Ratio
26.10
Quick Ratio
26.10
Debt / Equity Ratio
0.00
Debt / EBITDA
-0.04
Debt / FCF
-0.01
OCF / Debt
-143.15
Interest Coverage
0.00
Altman Z-Score
78.78
Piotroski F-Score
2

Margins & Profitability

Gross Profit Margin
96.0%
Operating Profit Margin
-11441.4%
EBITDA Margin
-1549.9%
Net Profit Margin
-1570.8%
FCF Margin
-9694.1%
Adj. FCF Margin
-12050.9%
SBC / Revenue
1800.0%
SBC Impact (per share)
-24.3%

Returns

Return on Assets
-2.5%
Return on Equity
-3.5%
Return on Invested Capital
-18.5%
Return on Capital Employed
-18.5%
Return on Tangible Assets
-2.5%

Historical Growth (CAGR)

Revenue CAGR 3Y
-20.5%
Revenue CAGR 5Y
16.6%
Revenue CAGR 10Y
N/A
EPS CAGR 3Y
100.0%
EPS CAGR 5Y
57.7%
EPS CAGR 10Y
N/A
FCF CAGR 3Y
-66.9%
FCF CAGR 5Y
-40.9%
FCF CAGR 10Y
N/A

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
11
EPS Growth Next 3Y
-807.7%
Revenue Growth Next 3Y
405.1%
Earnings Date
Nov 4, 2026
EPS Estimate (next Q)
-$0.94
EPS Growth Est (next Q)
-2.7%
Revenue Est (next Q)
$443.85K
Revenue Growth Est (next Q)
12.1%

Fair Value Estimates

Graham Number
N/A
Graham Upside
N/A
Lynch Fair Value
N/A
Lynch Upside
N/A
Price Target
$126.83
Price Target Upside
31.5%

Cash Flow

Operating Cash Flow
$-184.23M
Free Cash Flow
$-184.58M
Adj. Free Cash Flow
$-229.45M
FCF Per Share
-$2.78
OCF Per Share
-$2.77
OCF/S Ratio
-8160.5%

Income Statement

Revenue
$1.9M
Gross Profit
$1.83M
Operating Income
$-217.84M
EBITDA
$-29.51M
Net Income
$-29.91M
EPS (Diluted)
-$0.13
Revenue / Employee
$20.7K
Profit / Employee
$-325.1K
Employees
92

© 2026 bestshares.com. All rights reserved.